Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Alpha radiation emitter

DRUG CLASS:

Alpha radiation emitter

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	225Ac-FL-020 Sensitive: B - Late Trials 225Ac-FL-020 Sensitive : B	225Ac-FL-020 Sensitive: B - Late Trials 225Ac-FL-020 Sensitive : B
SSTR Expression	Neuroendocrine Tumor	SSTR Expression	Neuroendocrine Tumor	ORM-2110 Sensitive: C3 – Early Trials ORM-2110 Sensitive : C3	ORM-2110 Sensitive: C3 – Early Trials ORM-2110 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + lintuzumab-Ac225 Sensitive: C3 – Early Trials venetoclax + lintuzumab-Ac225 Sensitive : C3	venetoclax + lintuzumab-Ac225 Sensitive: C3 – Early Trials venetoclax + lintuzumab-Ac225 Sensitive : C3
TMPRSS2-ERG fusion	Prostate Cancer	TMPRSS2-ERG fusion	Prostate Cancer	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3
RB deletion	Prostate Cancer	RB deletion	Prostate Cancer	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3
CD33 expression	Acute Myelogenous Leukemia	CD33 expression	Acute Myelogenous Leukemia	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3	lintuzumab-Ac225 Sensitive: C3 – Early Trials lintuzumab-Ac225 Sensitive : C3
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3	RYZ101 Sensitive: C3 – Early Trials RYZ101 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	I-131-apamistamab Sensitive: C3 – Early Trials I-131-apamistamab Sensitive : C3	I-131-apamistamab Sensitive: C3 – Early Trials I-131-apamistamab Sensitive : C3
ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical Ac-225 ErbB3 targeted radiotherapy Sensitive : D